Patents by Inventor Xuelian ZHAO

Xuelian ZHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BROADLY NEUTRALIZING BINDING MOLECULES AGAINST MARBURGVIRUSES
    Publication number: 20230235029
    Abstract: Disclosed herein is a novel class of isolated binding molecules including monoclonal antibodies that targets a broadly conserved epitope within the marburgvirus species. Certain aspects provide an effective treatment option for hemorrhagic fever caused by marburgviruses.
    Type: Application
    Filed: July 20, 2021
    Publication date: July 27, 2023
    Inventors: Mohammad Javad Aman, Yimeng Wang, Shweta Kailasan, Xuelian Zhao, Andrey Galkin, Katie A. Howell, Erica Ollmann Saphire, Yuxing Li
  • Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
    Patent number: 11186626
    Abstract: This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: November 30, 2021
    Assignees: INTEGRATED BIOTHERAPEUTICS, INC., UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Mohammad Javad Aman, Katie A. Howell, Frederick Wayne Holtsberg, Xuelian Zhao, Yuxing Li
  • BROADLY NEUTRALIZING ANTIBODY TARGETING THE EBOLAVIRUS GLYCOPROTEIN INTERNAL FUSION LOOP
    Publication number: 20200040065
    Abstract: This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.
    Type: Application
    Filed: October 9, 2017
    Publication date: February 6, 2020
    Inventors: Mohammad Javad AMAN, Katie A. HOWELL, Frederick Wayne HOLTSBERG, Xuelian ZHAO, Yuxing LI
  • Fully human antibody against respiratory syncytical virus
    Patent number: 10149903
    Abstract: Disclosed are an antibody (preferably a fully human antibody R66) against respiratory syncytical virus RSV, encoding nucleic acids thereof, a vetor and a host cell comprising the same, and a preparation method thereof. Disclosed are also a use of the antibody (preferably a fully human antibody R66) against RSV in the prevention and treatment of RSV-related diseases, and a use of the same in detecting TSV. The above antibody against RSV is preferably a fully human monoclonal antibody. Compared with other animal-derived (e.g., murine) anti-RSV antidodies, the immunogenicity caused by species differences is greatly reduced. With good specificity and affinity, if used for clinic, it will greatly reduce side effects.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: December 11, 2018
    Assignee: ELITEIMMUNE INC.
    Inventors: Xuelian Zhao, Guohua Liu, Quanying Wang
  • FULLY HUMAN ANTIBODY AGAINST RESPIRATORY SYNCYTICAL VIRUS
    Publication number: 20180264103
    Abstract: Disclosed are an antibody (preferably a fully human antibody R66) against respiratory syncytical virus RSV, encoding nucleic acids thereof, a vetor and a host cell comprising the same, and a preparation method thereof. Disclosed are also a use of the antibody (preferably a fully human antibody R66) against RSV in the prevention and treatment of RSV-related diseases, and a use of the same in detecting TSV. The above antibody against RSV is preferably a fully human monoclonal antibody. Compared with other animal-derived (e.g., murine) anti-RSV antidodies, the immunogenicity caused by species differences is greatly reduced. With good specificity and affinity, if used for clinic, it will greatly reduce side effects.
    Type: Application
    Filed: May 29, 2018
    Publication date: September 20, 2018
    Inventors: Xuelian ZHAO, Guohua LIU, Quanying WANG